



# MASSACHUSETTS LIFE SCIENCES CENTER

**FOR IMMEDIATE RELEASE:**

**Date: 1/27/09**

Contact:  
Angus McQuilken  
Vice President for Communications  
Cell: 617-921-7749  
amcquilken@masslifesciences.com

**Massachusetts Life Sciences Center Adds Three New Members to Scientific  
Advisory Board**

*Jonathan Fleming, Doug Cole and Jean George add additional investment expertise to  
distinguished group of advisors*

**Boston, Massachusetts, (January 27, 2009)** –The Massachusetts Life Sciences Center (“MLSC”), a quasi-public agency tasked with implementing the State’s \$1 billion Life Sciences Initiative, today announced the addition of three new members to the organization’s Scientific Advisory Board (SAB). The three additions, experts representing the Massachusetts scientific investment community, bring the Board’s total membership to fifteen. The Life Sciences Center’s SAB provides technical guidance and oversight around the Center’s scientific funding and programmatic decisions. The expert panel ensures that decisions made at the Center are made based on merit and with scientific credibility and transparency. The Board is chaired by Dr. Harvey F. Lodish, Member of the Whitehead Institute for Biomedical Research and Professor of Biology and Professor of Bioengineering at Massachusetts Institute of Technology.

“The members of our Scientific Advisory Board bring vast experience in life sciences, and represent a diverse range of leadership positions in industry and academia,” said Dr. Susan Windham-Bannister, President & CEO of the MLSC. “The addition of these new members, each of whom brings expertise from the Massachusetts investment community, will position the SAB and the Center for success in accomplishing our goals.”

"As the Center increases its investments in early stage Massachusetts life sciences companies, we are indeed fortunate to have these three talented and distinguished individuals joining the Center's Scientific Advisory Board," said Dr. Lodish. "Alongside the current SAB members, they will play an essential role in guiding the investments of the Center, and supporting the Center's mission of job creation and scientific advancement."

Biographies of the three new members are below:

### **Jonathan Fleming, MPA, Managing General Partner, Oxford Bioscience Partners**

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.

Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master's degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is on the board of Asterand plc (LSE: ATD). He is also a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.

### **Doug Cole, MD, General Partner, Flagship Ventures**

Doug joined Flagship Ventures in 2001 where he focuses on Life Science investments. He came to Flagship with significant industrial experience and a strong academic background.

In 1996, Doug joined Cytotherapeutics, in Providence, RI. As Medical Director he oversaw various research and clinical activities related to the company's cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA, where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas.

At Flagship, Doug has led investments in [CombinatoRx](#) (NASDAQ: CRXX), [Tetraphase](#), [Alvine Pharmaceuticals](#), [Concert Pharmaceuticals](#), and [Quanterix](#). He co-founded [Ensemble Discovery](#) with Noubar Afeyan and Professor David Liu of Harvard University, and he served as CEO of the company in its initial stages. He currently serves on the Boards of Directors of Ensemble Discovery, Tetraphase, Concert Pharmaceuticals, Quanterix, [AVEO Pharmaceuticals](#), and [CGI Pharmaceuticals](#), and is an Observer on the Board of Directors of [Alvine](#). He formerly served on the Board of Directors of CombinatoRx and Morphotek. He is a member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation and the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, and serves on the Board of Directors of the Birch Rock Camp in Waterford, ME.

He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA. In 1992, Doug was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations. Doug holds an AB *magna cum laude* with High Distinction in English from Dartmouth College, where he was a Senior Fellow and a member of Phi Beta Kappa, and an MD from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha.

### **Jean M. George, Partner, Advanced Technology Ventures**

Jean George joined Advanced Technology Ventures as a Partner in 2002, with 20 years of experience in the biopharmaceutical industry, including 10 years at Genzyme Corporation. Jean assesses new deals in the life sciences and therapeutics markets, and utilizes her operational skills to actively assist portfolio companies on their strategic planning and development. Jean is currently on the Boards of NuGenesis Technologies Corp. and Microbia, Inc.

Prior to joining ATV, Jean was a Director at BancBoston Ventures, where she led the health care team's investment activity in NuGenesis Technologies Corp., Microbia, Inc., Syntonix Pharmaceuticals and Neurometrix, Inc. Previously, during Jean's tenure at Genzyme, she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. Jean was a member of the founding team of the Genzyme Tissue Repair Division, and held responsibilities for identifying new product opportunities and potential acquisition candidates for the Therapeutic Products Division. In addition to her extensive operating background, Jean spent six years working in chemistry and bioresearch fields.

Jean earned an MBA from Simmons College Graduate School of Management and a BS in Biology from the University of Maine.

### **About the Massachusetts Life Sciences Center**

The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, \$1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit [www.masslifesciences.com](http://www.masslifesciences.com).

###